Looks like many of the ducks are in a row:
"LevPharma has entered into an exclusive world-wide license with
Sanquin for the use of C1-INH for the treatment of AMI as well as HAE."
"Lev’s C1 inhibitor, to be marketed as Cinryze™, has been
granted orphan drug status for the treatment and prevention of HAE,
potentially securing, upon approval, market exclusivity for seven years.
Lev has also received fast track designation status from the FDA, which
facilitates the development and expedites the review of drugs and
biologics intended to treat serious or life-threatening conditions and
that demonstrate the potential to address unmet medical needs."
And they have ~40,000,000 in cash?
Hmmm, I think I'll dip my beak!
Step aside son, you're blockin' the MOMO!
Disproving absence of evidence should be easy, show the evidence of.
